BioStock: Ultimovacs on track to phase II readout

Cancer vaccines are quickly gaining popularity in the international biotech community, especially since household names like Moderna and BioNTech have stepped into the ring. Norwegian biotech Ultimovacs is poised to ride this wave of momentum as it approaches phase II readouts with its universal cancer vaccine UV1. BioStock spoke with CEO Carlos de Sousa to hear about the progress made in Q4 2022, and how UV1 could rival personalised mRNA vaccines.

Read the interview with Carlos de Sousa at biostock.se:

Ultimovacs på väg mot fas II-avläsning - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/